This review presents an overview of the field of immunoliposome-mediated ta
rgeting of anticancer agents. First, problems that are encountered when imm
unoliposomes are used for systemic anticancer drug delivery and potential s
olutions are discussed. Second, an update is given of the in vivo results o
btained with immunoliposomes in tumor models. Finally, new developments on
the utilization of immunoliposomes for the treatment of cancer are highligh
ted. (C) 1999 Elsevier Science B.V. All rights reserved.